Abstract
Early detection of colorectal cancer (CRC) through screening is the most effective method to reduce morbidity as well as mortality from this disease. Fecal immunochemical test (FIT)-based screening has shown to be effective, especially in multi-round population-based screening. However, its sensitivity and specificity are suboptimal, leaving room for improvement. In this perspective, the development journey of a new screening test, the multitargetFIT (mtFIT), which outperforms FIT, is described from discovery down to large-scale clinical utility testing and health technology assessment.